Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T for relapsed or refractory central nervous system diffuse large B-cell lymphoma
ChiCTR2000028781Phase 2Recruiting
- Sponsor
- Yunnan Cancer Hospital
- Start
- Oct 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19 CAR-T cells in diffuse large B-cell lymphoma (DLBCL) and Diffuse Large B-Cell Primary Central Nervous System Lymphoma, sponsored by Yunnan Cancer Hospital. Primary endpoint: CAR gene. Started Oct 2019; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Diffuse Large B-Cell Primary Central Nervous System Lymphoma
Beyond the preview
Go deeper on ChiCTR2000028781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028781.